Company Filing History:
Years Active: 2022
Title: Innovations of Xin Pan in Topical Preparations
Introduction
Xin Pan is an accomplished inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of topical preparations. His innovative work focuses on enhancing the efficacy of treatments for skin conditions caused by anti-tumor drugs.
Latest Patents
Xin Pan holds a patent for a topical preparation containing vitamin K1 and its preparation method. This formulation includes 0.01-5% of vitamin K1, 0.1-25% of a transdermal enhancer, and 70-99% of a matrix for the topical preparation. The transdermal enhancer is composed of urea, menthol, and oil in a specific mass ratio. This topical preparation is designed to treat moderate and severe skin toxicity associated with epidermal growth factor receptor (EGFR) related anti-tumor drugs. It effectively addresses conditions such as acne-like rash, pruritus, red swelling, dry skin, and mucositis. The formulation increases the likelihood of vitamin K1 reaching focus sites in the dermal layer, providing rapid relief from skin diseases caused by these treatments.
Career Highlights
Xin Pan is currently associated with Yangzijiang Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd. His work in this company has been pivotal in advancing pharmaceutical innovations. He has demonstrated a strong commitment to improving patient outcomes through his research and development efforts.
Collaborations
Xin Pan collaborates with notable colleagues, including Haihua Ni and Xinguo Jiang. Their combined expertise contributes to the success of their projects and enhances the overall impact of their innovations in the pharmaceutical industry.
Conclusion
Xin Pan's contributions to the field of topical preparations highlight his dedication to addressing critical health challenges. His innovative patent for a vitamin K1-based formulation exemplifies the potential for advancements in treating skin toxicity from anti-tumor therapies. Through his work, he continues to make a significant impact in the pharmaceutical sector.